UnitedHealth (UNH): Director Granted 260 Deferred Stock Units

This Form 4 reports that Charles D. Baker, a director of UnitedHealth Group Inc. (UNH), was granted 260 deferred stock units as director compensation on 10/01/2025.

Rhea-AI Filing Summary

This Form 4 reports that Charles D. Baker, a director of UnitedHealth Group Inc. (UNH), was granted 260 deferred stock units as director compensation on 10/01/2025. The units were granted at a $0 per-unit price and are described as immediately vested but required to be retained until the director leaves the Board. After the reported grant, the filing shows 1,516 shares (or equivalent units) beneficially owned by Mr. Baker. The form was signed by Faraz A. Choudhry, Attorney-in-Fact on 10/03/2025.

Positive

• 260 deferred stock units were granted as regular director compensation and are immediately vested
• Filing discloses 1,516 total shares/units owned after the grant, providing transparency on insider holdings

Negative

• None.

Insider Trade Summary

Grant/Award: 260 shares

Grant/Award 1 txn

Insider Baker Charles D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	260	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,516 shares (Direct)

Footnotes (1)

1. F1. Represents deferred stock units that are granted as regular quarterly compensation for service as a director of UnitedHealth Group. Deferred stock units are immediately vested, but must be retained by the director until the director's completion of service on the Board.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 4 for UnitedHealth (UNH) report?

The Form 4 reports a grant of 260 deferred stock units to director Charles D. Baker on 10/01/2025 at a $0 price.

Are the deferred stock units vested for the UNH director?

Yes. The filing states the deferred stock units are immediately vested but must be retained until the director completes service on the Board.

How many shares does Charles D. Baker beneficially own after the transaction?

The Form 4 shows 1,516 shares or units beneficially owned following the reported transaction.

Who signed the Form 4 for Charles D. Baker?

The Form 4 was signed by Faraz A. Choudhry, Attorney-in-Fact on 10/03/2025.

What was the transaction type and price on the Form 4?

The transaction code is listed as a grant (Code A) of deferred stock units with a reported price of $0.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/03/2025 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Baker Charles D.

(Last) (First) (Middle)

C/O UNITEDHEALTH GROUP INCORPORATED

1 HEALTH DRIVE

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITEDHEALTH GROUP INC [ UNH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/01/2025		A		260(1)	A	$0	1,516	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents deferred stock units that are granted as regular quarterly compensation for service as a director of UnitedHealth Group. Deferred stock units are immediately vested, but must be retained by the director until the director's completion of service on the Board.

Remarks:

	Faraz A. Choudhry, Attorney-in-Fact for Charles D. Baker	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.